Artificial Intelligence in Diagnostics Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global Artificial Intelligence in Diagnostics Market, By Component

7.1. Artificial Intelligence in Diagnostics Market, by Component Type, 2024-2033
7.1.1. Hardware
7.1.1.1. Market Revenue and Forecast (2021-2033)
7.1.2. Software
7.1.2.1. Market Revenue and Forecast (2021-2033)
7.1.3. Services
7.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 8. Global Artificial Intelligence in Diagnostics Market, By Diagnosis Type

8.1. Artificial Intelligence in Diagnostics Market, by Diagnosis Type, 2024-2033
8.1.1. Radiology
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Pathology
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Cardiology
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Oncology
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Neurology
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Chest and Lung
8.1.6.1. Market Revenue and Forecast (2021-2033)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Artificial Intelligence in Diagnostics Market, Regional Estimates and Trend Forecast

9.1. North America
9.1.1. Market Revenue and Forecast, by Component (2021-2033)
9.1.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Component (2021-2033)
9.1.3.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Component (2021-2033)
9.1.4.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Component (2021-2033)
9.2.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Component (2021-2033)
9.2.3.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Component (2021-2033)
9.2.4.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Component (2021-2033)
9.2.5.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Component (2021-2033)
9.2.6.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Component (2021-2033)
9.3.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Component (2021-2033)
9.3.3.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Component (2021-2033)
9.3.4.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Component (2021-2033)
9.3.5.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Component (2021-2033)
9.3.6.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Component (2021-2033)
9.4.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Component (2021-2033)
9.4.3.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Component (2021-2033)
9.4.4.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Component (2021-2033)
9.4.5.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Component (2021-2033)
9.4.6.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Component (2021-2033)
9.5.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Component (2021-2033)
9.5.3.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Component (2021-2033)
9.5.4.2. Market Revenue and Forecast, by Diagnosis Type (2021-2033)

Chapter 10. Company Profiles

10.1. Siemens Healthcare GmbH
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. GE Healthcare
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Aidoc
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Imagen Technologies
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. AliveCor
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Zebra Medical Vision
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Vuno Inc.
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. IDx Technologies Inc.
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Neural Analytics
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Riverain Technologies
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives

Chapter 11. Research Methodology

11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions

Chapter 12. Appendix

12.1. About Us
12.2. Glossary of Terms